Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-067011
Filing Date
2025-05-08
Accepted
2025-05-08 16:16:35
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-20250331.htm   iXBRL 10-Q 2304126
2 EX-31.1 trvi-ex31_1.htm EX-31.1 17727
3 EX-31.2 trvi-ex31_2.htm EX-31.2 17701
4 EX-32.1 trvi-ex32_1.htm EX-32.1 12037
5 EX-32.2 trvi-ex32_2.htm EX-32.2 11997
  Complete submission text file 0000950170-25-067011.txt   9312668

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20250331.xsd EX-101.SCH 1125986
71 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20250331_htm.xml XML 1771742
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 25926383
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)